Novartis has broadened the indications for its Votubia drug after getting EU approval

News Hour:

Novartis has broadened the indications for its Votubia drug, the company said on Tuesday, when the European Union approved its use to treat refractory partial-onset seizures in patients with tuberous sclerosis complex.

Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex, the Basel-based pharmaceuticals company said in a statement, reports Reuters.

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland

The decision marks the third TSC-related indication for Votubia in the EU, where it is also approved to treat subependymal giant cell astrocytoma and renal angiomyolipomas.

Tuberous sclerosis complex is a rare genetic disorder affecting up to one million people worldwide. Approximately 85 percent of individuals with TSC are affected by epilepsy, and uncontrolled seizures associated with TSC can be debilitating for patients.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Anurag Kashyap shoots Kubra Saith 7 times nude and made her cry for frontal nudity scene [Video]
Marriott's acquisition of starwood has antitrust authorization from saudi arabia and mexico
Update on China's ministry of commerce review of Marriott and Starwood merger
Paperfly launches delivery services covering 64 districts in Bangladesh

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: